A program for personalized cancer treatment at The Chinese University of Hong Kong
Comprehensive Precision Oncology Program at The Chinese University of Hong Kong
This study is testing a new program that aims to personalize cancer treatments for people with advanced gastrointestinal cancers by matching their unique cancer types to the best drug therapies and clinical trials.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 200 (estimated) |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Sponsor | Chinese University of Hong Kong Academic / other |
| Locations | 1 site (Hong Kong) |
| Trial ID | NCT04724070 on ClinicalTrials.gov |
What this trial studies
This project aims to create a comprehensive precision oncology platform to tailor drug therapies for patients with advanced gastrointestinal cancers. It focuses on optimizing genomic matching to connect patients with unique cancer subtypes to relevant clinical trials for novel therapies. Additionally, the study will establish a personalized drug screening platform using patient-derived cancer models and investigate the feasibility of genomic sequencing through circulating tumor DNA. A biobank of tumor tissues will also be constructed to support these efforts.
Who should consider this trial
Good fit: Ideal candidates include patients aged 18 to 75 with confirmed gastrointestinal cancers who require systemic therapy and are willing to participate in clinical trials.
Not a fit: Patients who are medically unfit for systemic therapy or have multiple invasive cancers may not benefit from this program.
Why it matters
Potential benefit: If successful, this program could significantly improve treatment outcomes for patients with advanced gastrointestinal cancers by providing personalized therapy options.
How similar studies have performed: Other studies have shown promise in precision oncology approaches, indicating potential success for this program.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Must be aged between 18 to 75 years * Must have ECOG performance status of 0 to 1 * Must have histologically/cytologically confirmed cancers of certain subtype * Medically fit patients who would need systemic therapy as part of their oncological treatment in any one or more of the following oncological setting(s): palliative, neoadjuvant, adjuvant, concurrent with radiotherapy. This includes patients who have limited systemic therapeutic options for their cancers and are candidates for clinical trials. * Able to give written informed consent * Willing to have blood samples taken. * Availability of an archived paraffin-embedded tumor block Exclusion Criteria: * Patients who refuse or are medically unfit for systemic therapy for their cancer * Patients with more than one invasive cancers diagnosed over the last FIVE years. * Patients without measurable tumor lesions on radiological imaging * Patients who are unable to give written informed consent.
Where this trial is running
Hong Kong
- The Chinese University of Hong Kong — Hong Kong, Hong Kong (Recruiting)
Study contacts
- Study coordinator: Brigette MA, MD
- Email: brigette@clo.cuhk.edu.hk
- Phone: 22939871
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.